Low-dose decitabine versus best supportive care in elderly patients with intermediate-or high-risk myelodysplastic syndrome (MDS) ineligible for intensive …

M Lübbert, S Suciu, L Baila, BH Rüter… - Journal of clinical …, 2011 - ascopubs.org
Purpose To compare low-dose decitabine to best supportive care (BSC) in higher-risk
patients with myelodysplastic syndrome (MDS) age 60 years or older and ineligible for …
被引用次数：664 相关文章

Low-dose decitabine versus best supportive care in elderly patients with intermediate-or high-risk myelodysplastic syndrome (MDS) ineligible for intensive …

M Lübbert, S Suciu, L Baila… - Journal of clinical …, 2011 - pubmed.ncbi.nlm.nih.gov
Purpose To compare low-dose decitabine to best supportive care (BSC) in higher-risk
patients with myelodysplastic syndrome (MDS) age 60 years or older and ineligible for …

Low-dose decitabine versus best supportive care in elderly patients with intermediate-or high-risk myelodysplastic syndrome (MDS) ineligible for intensive …

M Lübbert, B Labar, PW Wijermans - Journal of clinical oncology, 2011 - croris.hr
Sažetak Purpose was to compare low-dose decitabine to best supportive care (BSC) in
higher-risk patients with myelodysplastic syndrome (MDS) age 60 years or older and …

Low-dose decitabine versus best supportive care in elderly patients with intermediate-or high-risk myelodysplastic syndrome (MDS) ineligible for intensive …

M Lübbert, S Suciu, L Baila, BH Rüter… - Journal of Clinical …, 2011 - europepmc.org
Low-dose decitabine versus best supportive care in elderly patients with intermediate- or
high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results …

Low-Dose Decitabine Versus Best Supportive Care in Elderly Patients With Intermediate-or High-Risk Myelodysplastic Syndrome (MDS) Ineligible for Intensive …

M Lübbert, S Suciu, L Baila, BH Rüter… - Journal of Clinical …, 2011 - cir.nii.ac.jp
抄録< jats: sec>< jats: title> Purpose</jats: title>< jats: p> To compare low-dose decitabine to
best supportive care (BSC) in higher-risk patients with myelodysplastic syndrome (MDS) age …

[引用][C] Low-dose decitabine versus best supportive care in elderly patients with intermediate-or high-risk myelodysplastic syndrome (MDS) ineligible for intensive …

M Lubbert, S Suciu, L Baila, BH Ruter, U Platzbecker… - 2011 - repository.ubn.ru.nl
PURPOSE: To compare low-dose decitabine to best supportive care (BSC) in higher-risk
patients with myelodysplastic syndrome (MDS) age 60 years or older and ineligible for …

[引用][C] Low-Dose Decitabine Versus Best Supportive Care in Elderly Patients With Intermediate-or High-Risk Myelodysplastic Syndrome (MDS) Ineligible for Intensive …

M LÜBBERT, S SUCIU, F BEELDENS… - Journal of clinical …, 2011 - pascal-francis.inist.fr
Low-Dose Decitabine Versus Best Supportive Care in Elderly Patients With Intermediate- or
High-Risk Myelodysplastic Syndrome (MDS) Ineligible for Intensive Chemotherapy: Final …

Low-dose decitabine versus best supportive care in elderly patients with intermediate-or high-risk myelodysplastic syndrome (MDS) ineligible for intensive …

M Lübbert, B Labar, PW Wijermans - Journal of clinical oncology, 2011 - croris.hr
Sažetak Purpose was to compare low-dose decitabine to best supportive care (BSC) in
higher-risk patients with myelodysplastic syndrome (MDS) age 60 years or older and …

[引用][C] Low-dose decitabine versus best supportive care in elderly patients with intermediate-or high-risk myelodysplastic syndrome (MDS) ineligible for intensive …

M LUBBERT - J Clin Oncol, 2011 - cir.nii.ac.jp
Low-dose decitabine versus best supportive care in elderly patients with intermediate- or
high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy : final results …

[引用][C] Low-Dose Decitabine Versus Best Supportive Care in Elderly Patients With Intermediate-or High-Risk Myelodysplastic Syndrome (MDS) Ineligible for Intensive …

M LÜBBERT, S SUCIU, L BAILA… - Journal of …, 2011 - American Society of Clinical …